Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
Recruiting · NCT06399640 · Registry updated 2026-08-19Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, bone marrow disorder, hematologic disorder, leukemia, myelodysplastic syndrome, myeloid leukemia, neoplasm | Recruiting | Phase 1 | 2026-08-19 | NCT06399640 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Karyopharm Therapeutics Inc | 25 |
| National Cancer Institute (NCI) | 3015 |
| Vanderbilt-Ingram Cancer Center | 42 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Baptist Health Care Corporation | Memphis | United States | 1 |
| Vanderbilt University/Ingram Cancer Center | Nashville | United States | 12 |